October 4th, 2024 – Bali, Indonesia: RGCC, a leader in advanced diagnostic technologies, and the Indonesian Association of Surgical Oncology Experts (PERABOI) have formally signed a Memorandum of Understanding (MOU) with PT Wapindo Jasaartha (Klinik Simas Sehat) to launch a clinical study that will investigate the role of liquid biopsy (Circulating Tumor Cells) for monitoring treatment outcomes in breast cancer patients undergoing neoadjuvant chemotherapy.
The study, titled “Clinical Application of Circulating Tumor Cells (CTC) Profiles to Monitor Pathological Responses and Distant Metastasis-Free Survival in Breast Cancer Undergoing Neoadjuvant Chemotherapy”, aims to explore the potential of circulating tumor cell (CTC) analysis as a predictive tool for pathological and clinical outcomes in breast cancer patients receiving neoadjuvant chemotherapy. The study is expected to provide valuable insights into how CTC profiles can assist in monitoring tumor response and survival outcomes, potentially transforming the way breast cancer is managed in clinical settings.
The clinical trial will be an observational, prospective cohort study that involves about 60 patients with stage II-III triple-negative breast cancer (TNBC) and HER2-enriched subtypes. The study will be conducted across three hospitals in Indonesia, using RGCC’s proprietary Oncotrace and Onconomics panels to evaluate CTC profiles in patients at various stages of their treatment.
Key outcomes for the study include evaluating residual cancer burden, clinical response according to RECIST (Response Evaluation Criteria in Solid Tumors), and metastatic-free survival. Secondary objectives include assessing the ability of liquid biopsy (CTC) as an independent variable for prognosis and treatment monitoring.
The signing ceremony took place on October 4, 2024, in Bali, Indonesia, with more than 50 board members from PERABOI in attendance. Dr. Ioannis Papasotiriou, Director of RGCC, was present to formalize the agreement and provide insights into the significance of this collaboration for the advancement of cancer diagnostics and personalized medicine.
“We are excited to partner with PERABOI and PT Wapindo Jasaartha on this important clinical study. The use of liquid biopsy to monitor treatment responses in breast cancer patients could offer a less invasive, more precise way to track the progression of the disease, ultimately helping to guide more effective treatments and improve patient outcomes,” said Dr. Ioannis Papasotiriou, Director of RGCC.
The collaboration between RGCC, PERABOI, and Klinik Simas Sehat marks a significant step forward in the clinical application of advanced diagnostic technologies and highlights the growing role of liquid biopsy in personalized oncology care.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For more info visit: rgcc-international.com
About PERABOI
The Indonesian Association of Surgical Oncology Experts (PERABOI) is a professional organization focused on the advancement of surgical oncology in Indonesia. PERABOI is committed to advancing medical knowledge and improving the precision of cancer diagnostics and therapies, with the goal of enhancing treatment accuracy and patient outcomes across the country.
About PT Wapindo Jasaartha (Klinik Simas Sehat)
PT Wapindo Jasaartha, (Klinik Simas Sehat), is a healthcare provider committed to delivering high-quality medical services in Indonesia.
For general inquiries, please contact: office@rgcc-international.com